A. Rubagotti
- Cancer Research top 1%
- Breast Cancer Treatment Studies 27
- Oncology top 2%
- Cancer Treatment and Pharmacology 18
- HER2/EGFR in Cancer Research 9
- Reproductive Medicine top 1%
- Ovarian cancer diagnosis and treatment 14
- Genetics top 1%
- Estrogen and related hormone effects 28
- Obstetrics and Gynecology top 2%
-
- Prostate Cancer Treatment and Research 25
- Prostate Cancer Diagnosis and Treatment 9
-
- Lymphoma Diagnosis and Treatment 15
A. Rubagotti
127 papers receiving 3.5k citations
Peers
Comparison fields: 5 of 103
- Cancer Research 1.2k
- Oncology 1.6k
- Reproductive Medicine 494
- Genetics 1.3k
- Obstetrics and Gynecology 253
Countries citing papers authored by A. Rubagotti
This map shows the geographic impact of A. Rubagotti's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Rubagotti with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Rubagotti more than expected).
Fields of papers citing papers by A. Rubagotti
This network shows the impact of papers produced by A. Rubagotti. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Rubagotti. The network helps show where A. Rubagotti may publish in the future.
Co-authorship network
The 25 scholars most cited alongside A. Rubagotti, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2023 | 1 | |
| 2 | 2020 | 2 | |
| 3 | 2018 | 11 | |
| 4 | 2015 | 1 | |
| 5 | 2014 | 44 | |
| 6 | 2013 | 18 | |
| 7 | 2006 | 4 | |
| 8 | 2006 | 158 | |
| 9 | 2003 | 24 | |
| 10 | 2002 | 34 | |
| 11 | Fludarabine in combination with cyclophosphamide or with cyclophosphamide plus mitoxantrone for relapsed or refractory low-grade non-Hodgkin's lymphoma. | 2001 | 24 |
| 12 | 2001 | 11 | |
| 13 | 1999 | 20 | |
| 14 | 1996 | 9 | |
| 15 | 1993 | 3 | |
| 16 | 1993 | 48 | |
| 17 | 1993 | 8 | |
| 18 | 1993 | 7 | |
| 19 | 1989 | 20 | |
| 20 | 1987 | 3 |
About A. Rubagotti
A. Rubagotti is a scholar working on Cancer Research, Oncology, Pathology and Forensic Medicine, Reproductive Medicine and Pulmonary and Respiratory Medicine, having authored 131 papers that have together received 3.7k indexed citations. Recurring topics across this work include Estrogen and related hormone effects (28 papers), Breast Cancer Treatment Studies (27 papers), Prostate Cancer Treatment and Research (25 papers), Cancer Treatment and Pharmacology (18 papers), Lymphoma Diagnosis and Treatment (15 papers), Ovarian cancer diagnosis and treatment (14 papers), Prostate Cancer Diagnosis and Treatment (9 papers) and HER2/EGFR in Cancer Research (9 papers). The work is most often cited by research in Cancer Research (1.2k citations), Oncology (1.6k citations), Reproductive Medicine (494 citations), Genetics (1.3k citations) and Obstetrics and Gynecology (253 citations). A. Rubagotti has collaborated with scholars based in Italy, United Kingdom and United States. Frequent co-authors include Francesco Boccardo, Pamela Guglielmini, P Sismondi, M. Mesiti, R. Rosso, D. Amoroso, Matteo Puntoni, V. Distante, Pierfranco Conté and Mauro Porpiglia. Their work appears in journals such as Journal of Clinical Oncology, European Journal of Cancer, Oncology, Annals of Oncology and Gynecologic Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.